Title:
Tissue engineering a pancreatic substitute based on recombinant intestinal endocrine cells

dc.contributor.advisor Sambanis, Athanassios
dc.contributor.author Bara, Heather Lynn en_US
dc.contributor.committeeMember Bellamkonda, Ravi
dc.contributor.committeeMember Garcia, Anes
dc.contributor.committeeMember Le Doux, Joseph
dc.contributor.committeeMember Thule, Peter
dc.contributor.department Biomedical Engineering en_US
dc.date.accessioned 2009-01-22T15:51:44Z
dc.date.available 2009-01-22T15:51:44Z
dc.date.issued 2008-11-18 en_US
dc.description.abstract Cell-based treatments for insulin-dependent diabetes (IDD) may provide more physiologic regulation of blood glucose levels than daily insulin injections, thereby reducing the occurrence of secondary complication associated with IDD. An autologous cell source is especially attractive for regulatory and ethical reasons and for circumventing the need for immunosuppression, which is currently standard for islet transplantation. Our approach focuses on using adult non-β-cells engineered for physiologic insulin secretion. Specifically, we utilize enteroendocrine L-cells, which naturally exhibit regulated secretion of GLP-1 in response to physiologic stimuli, and upon genetic engineering, co-secrete insulin in a regulated manner. The overall goal of this project is to develop a tissue engineered pancreatic substitute based on a recombinant enteroendocrine cell line and test the efficacy of the pancreatic substitute by implantation into diabetic mice. The specific aims of this thesis were to (1) to modify murine L-cells for regulated insulin secretion and evaluate the insulin secretion properties of the recombinant cells; (2) to incorporate insulin-secreting L-cells into an implantable construct containing small intestinal submucosa (SIS) and to evaluate insulin secretion from the construct in vitro; and (3) to test the efficacy of the tissue engineered pancreatic substitute in vivo by implanting it intraperitoneally in mice made diabetic by streptozotocin. Thus, this proposal takes a tissue engineered pancreatic substitute for IDD from in vitro development to in vivo testing. en_US
dc.description.degree Ph.D. en_US
dc.identifier.uri http://hdl.handle.net/1853/26627
dc.publisher Georgia Institute of Technology en_US
dc.subject GLUTag en_US
dc.subject L-cells en_US
dc.subject Tissue engineering en_US
dc.subject Diabetes en_US
dc.subject.lcsh Tissue engineering
dc.subject.lcsh Pancreas
dc.subject.lcsh Insulin
dc.title Tissue engineering a pancreatic substitute based on recombinant intestinal endocrine cells en_US
dc.type Text
dc.type.genre Dissertation
dspace.entity.type Publication
local.contributor.advisor Sambanis, Athanassios
local.contributor.corporatename Wallace H. Coulter Department of Biomedical Engineering
local.contributor.corporatename College of Engineering
relation.isAdvisorOfPublication 90a12241-15c3-4cbf-bc27-724c028b8fc1
relation.isOrgUnitOfPublication da59be3c-3d0a-41da-91b9-ebe2ecc83b66
relation.isOrgUnitOfPublication 7c022d60-21d5-497c-b552-95e489a06569
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
bara_heather_l_200812_phd.pdf
Size:
1.73 MB
Format:
Adobe Portable Document Format
Description: